Physician profile
Morteza Marandi
NPI 1366587594
$7,213.27
in general payments reported to CMS, 2019-2025
20 companies · $99.22 in 2025
The $99.22 reported for 2025 was less than what a typical Psychiatry provider received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,427 · 2020: $655 · 2021: $90.51 · 2022: $818 · 2023: $2,739 · 2024: $385 · 2025: $99.22.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Travel and Lodging: $1,930 · Food and Beverage: $1,293.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Travel and Lodging | $1,930.29 |
| Food and Beverage | $1,293.11 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Neurocrine Biosciences, INC. | $2,698.06 | 2020-2023 | |
| Janssen Pharmaceuticals, INC | $1,454.61 | 2019-2024 | Spravato |
| Sunovion Pharmaceuticals INC. | $840.98 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $442.97 | 2019-2024 | Uzedy |
| Sage Therapeutics, LLC | $416.00 | 2022 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $340.79 | 2022-2025 | Caplyta |
| Otsuka America Pharmaceutical, INC. | $242.32 | 2019-2020 | |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $174.97 | 2019 | |
| Allergan, INC. | $127.72 | 2019 | |
| Bioxcel Therapeutics, INC. | $125.00 | 2023 | Igalmi |
| Acadia Pharmaceuticals INC | $124.99 | 2019 | |
| Alkermes, INC. | $124.98 | 2019 | |
| Indivior INC. | $99.88 | 2020 |
7 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Morteza Marandi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.